MX2018005097A - Highly potent antibodies binding to death receptor 4 and death receptor 5. - Google Patents

Highly potent antibodies binding to death receptor 4 and death receptor 5.

Info

Publication number
MX2018005097A
MX2018005097A MX2018005097A MX2018005097A MX2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A MX 2018005097 A MX2018005097 A MX 2018005097A
Authority
MX
Mexico
Prior art keywords
death receptor
highly potent
antibodies binding
potent antibodies
death
Prior art date
Application number
MX2018005097A
Other languages
Spanish (es)
Inventor
Vasquez Maximiliano
Wang Lihong
Zhang April
Jin Kim Kyung
Ding Yi
Park Hangil
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of MX2018005097A publication Critical patent/MX2018005097A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
MX2018005097A 2015-10-30 2016-10-28 Highly potent antibodies binding to death receptor 4 and death receptor 5. MX2018005097A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248782P 2015-10-30 2015-10-30
PCT/US2016/059517 WO2017075484A2 (en) 2015-10-30 2016-10-28 Highly potent antibodies binding to death receptor 4 and death receptor 5

Publications (1)

Publication Number Publication Date
MX2018005097A true MX2018005097A (en) 2019-05-16

Family

ID=58630890

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005097A MX2018005097A (en) 2015-10-30 2016-10-28 Highly potent antibodies binding to death receptor 4 and death receptor 5.
MX2022000317A MX2022000317A (en) 2015-10-30 2018-04-25 Highly potent antibodies binding to death receptor 4 and death receptor 5.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000317A MX2022000317A (en) 2015-10-30 2018-04-25 Highly potent antibodies binding to death receptor 4 and death receptor 5.

Country Status (8)

Country Link
US (2) US10941204B2 (en)
EP (1) EP3368076A4 (en)
JP (2) JP6869553B2 (en)
KR (1) KR20180069066A (en)
CN (2) CN116333125A (en)
CA (1) CA3003033A1 (en)
MX (2) MX2018005097A (en)
WO (1) WO2017075484A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10941204B2 (en) 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
PL1648998T3 (en) 2003-07-18 2015-03-31 Amgen Inc Specific binding agents to hepatocyte growth factor
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AR059922A1 (en) 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CA2810016A1 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
FR2967676B1 (en) * 2010-11-19 2014-09-19 Agronomique Inst Nat Rech LUTEINIZING HORMONE LIGAND AND LIGAND-GONADOTROPHINE COMPLEX
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
WO2012167346A1 (en) * 2011-06-10 2012-12-13 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Anti-ricin antibodies and uses thereof
US9540442B2 (en) 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014063368A1 (en) * 2012-10-26 2014-05-01 中国医学科学院基础医学研究所 Humanized monoclonal antibody in extracellular domain of anti-human death receptor 5
MX366124B (en) * 2013-03-15 2019-06-27 Janssen Biotech Inc Interferon alpha and omega antibody antagonists.
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
SG10201913324PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
CA2974807A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
US10941204B2 (en) 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4

Also Published As

Publication number Publication date
CN116333125A (en) 2023-06-27
US10941204B2 (en) 2021-03-09
CN109195626A (en) 2019-01-11
WO2017075484A2 (en) 2017-05-04
US20190062443A1 (en) 2019-02-28
EP3368076A2 (en) 2018-09-05
WO2017075484A3 (en) 2017-06-22
US11891446B2 (en) 2024-02-06
CA3003033A1 (en) 2017-05-04
US20210238297A1 (en) 2021-08-05
JP2021104050A (en) 2021-07-26
KR20180069066A (en) 2018-06-22
JP7036471B2 (en) 2022-03-15
MX2022000317A (en) 2022-02-10
JP2019502653A (en) 2019-01-31
EP3368076A4 (en) 2019-08-28
CN109195626B (en) 2022-09-13
JP6869553B2 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
MX2022004072A (en) Factor xi antibodies and methods of use.
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
WO2018151821A8 (en) Antibodies to alpha-synuclein and uses thereof
MX2017003211A (en) Anti-met antibodies and compositions.
EA201691836A1 (en) ANTIBODIES TO MCAM AND RELATED METHODS OF THEIR APPLICATION
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019009498A (en) Fgf21 mimetic antibodies and uses thereof.
MX2018002924A (en) Highly potent monoclonal antibodies to angiogenic factors.
PH12019502694A1 (en) Anti-trkb antibodies
MX2022000317A (en) Highly potent antibodies binding to death receptor 4 and death receptor 5.
MA40363A (en) Rspo1 binding agents and uses thereof